Source comparison
MOTS-c Before and After Real Results: Study Comparison
The table below compares key findings from published research and clinical observations tracking MOTS-c outcomes across different timeframes and populations. Cell Metabolism (2015). Animal Model 15mg/kg administered 3× weekly for 4 weeks Insulin sensitivity an
This comparison does not assign a generated winner or score.
- The table below compares key findings from published research and clinical observations tracking MOTS-c outcomes across different timeframes and populations.
- Cell Metabolism (2015). Animal Model
- 15mg/kg administered 3× weekly for 4 weeks
- Insulin sensitivity and glucose tolerance
- Significant improvement by week 2, maximal effect at week 4
- MOTS-c prevented diet-induced insulin resistance in middle-aged mice. Human equivalency suggests 5–10mg doses 2–3× weekly
- Observational Case Series (2022). Metabolic Dysfunction
- 10mg administered 2× weekly for 12 weeks
- Fasting glucose, HbA1c, HOMA-IR
- Fasting glucose ↓12–18% by week 6, HbA1c ↓0.4–0.7% by week 12
- Meaningful metabolic improvement in insulin-resistant subjects. Minimal effect in metabolically healthy controls
- Athletic Performance Tracking (2023). Endurance Athletes
- 5mg administered 3× weekly for 8 weeks
- VO2max, time to exhaustion, lactate threshold
- VO2max ↑4–7% by week 4, endurance capacity ↑12–18% by week 8
- Performance gains appear earlier than body composition changes. AMPK-driven mitochondrial adaptation precedes fat loss
- Clinical Use (Real Peptides Client Data)
- 10–15mg administered 2× weekly for 16 weeks
- Body composition (DEXA), fasting insulin, subjective energy
- Body fat ↓2.5–4.2% by week 12 (with exercise + deficit), fasting insulin ↓20–35%
- Real MOTS-c before and after results require metabolic dysfunction at baseline plus consistent exercise. Not a monotherapy for fat loss